Trial to assess the safety and antitumor activity of GEN1057 on malignant solid tumors
This study, known as a Phase I trial, is looking at a new medication called GEN1057. It's designed for adult patients who have advanced solid tumours, which means their cancer has grown or spread. The main goals are to find out if GEN1057 is safe for people and what doses can be given. Researchers also want to see if it shows any signs of shrinking or stopping the cancer from growing. Because it's a very early study, it's one of the first times this medicine is being tested in humans. The information gathered will help decide if this medication should be studied further in larger trials.
At a glance
What is this study about?
This study is an early-stage clinical trial, sometimes called a Phase I trial. This means it's one of the first times a new medicine, known as GEN1057, is being given to people. The main purpose of studies like this is to carefully check if the new medicine is safe and to find the right dose. Think of it like taking a new car for its first test drive – you want to make sure it handles well and is safe before it goes onto the main roads.
The study is for adults who have solid tumours that are advanced or have spread to other parts of the body. These types of cancer include many different common cancers that affect organs like the breast, lung, bowel, or prostate, as well as others. The researchers are looking closely to see if GEN1057 can not only be given safely but also if it shows any early signs of helping to fight these cancers, for example, by stopping their growth or making them shrink.
While this is a very early step, the information gathered from this study is crucial. It helps doctors decide if GEN1057 is promising enough to move into bigger studies with more people. If successful, new treatments can offer more options for patients in the future.
Key takeaways
- It's a Phase I study, focusing on the safety of a new drug, GEN1057.
- The study is for adults with advanced solid tumours that have spread.
- It's one of the first times this new medicine is being tested in humans.
- Researchers will also look for early signs of the drug fighting cancer.
- Close monitoring for safety will be a key part of participating.
Who may be eligible?
To join this study, you must be an adult, aged 18 or older. There is no upper age limit, so people of all adult ages can be considered. The study is open to both men and women.
Critically, you must have been diagnosed with a solid tumour, which is a type of cancer that forms a lump, like breast cancer, lung cancer, or colon cancer. Your cancer should also be considered 'advanced' or 'metastatic', meaning it has grown significantly or has spread from where it started to other parts of your body.
Other specific health conditions, previous treatments, and how well your body is working (like your kidneys or liver) will also be checked by the study doctors to make sure it's safe for you to take part. This ensures the study includes people who are most likely to benefit and who can safely receive the new treatment.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- Are you 18 years old or older?
- Have you been diagnosed with an advanced or metastatic solid tumour?
- Are you well enough to participate in a clinical trial?
- Are you able to attend regular hospital or clinic visits?
What does participation involve?
If you decide to take part, you'll have regular visits to the study hospital or clinic. During these visits, doctors and nurses will carry out various tests, including blood tests, physical examinations, and scans (like CT or MRI scans) to check your health and how the treatment is affecting you and your cancer. You'll receive the study medication, GEN1057, which will be given in a specific way as determined by the study design. The frequency and duration of doses will be explained to you.
You'll be monitored very closely for any side effects or changes in your health. After you stop taking the study medication, there will be follow-up visits to continue checking on your health and well-being. The total length of your participation will depend on how you respond to the treatment and the study plan, but early-stage studies often involve close monitoring over several months.
Potential risks and benefits
Locations (1)
- —UnverifiedSpain
Common questions
What does 'Phase I' mean?
Phase I means it's an early study, looking mainly at the safety of a new medicine and finding the right dose in people for the first time.
What kind of cancer is this study for?
It's for adults with advanced solid tumours, which are cancers that form a lump and have grown or spread.
Will this drug cure my cancer?
This early study isn't designed to find a cure. Its main aim is to see if the drug is safe and shows any early signs of helping against cancer.
How long would I be in the study?
Your involvement would typically last several months, with close monitoring, but the exact duration depends on your response and the study plan.
Can I leave the study if I change my mind?
Yes, you can leave the study at any time, for any reason, without it affecting your future medical care.
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.